Cidara Therapeutics Inc

Cidara Therapeutics — Technical Presentation (July 2019)

14 slides from Cidara Therapeutics's technical presentation, Jul 29, 2019

  1. Slide 1: New Hope for Serious Infections: Topline Results, Phase 2 STRIVE Part B Trial for Rezafungin

    New Hope for Serious Infections Topline Results: Phase 2 STRIVE Part B Trial for Rezafungin July 29, 2019 © Cidara Therapeutics 2019 | Confidential Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from thos

  3. Slide 3: Executive Summary

    Executive Summary STRIVE B results successfully met all efficacy and safety objectives Results corroborate those from STRIVE A Uniform improvement in all efficacy outcomes comparing the 400/200mg dose versus caspofungin comparator Well tolerated with no concerning safety signals Results warrant cont

  4. Slide 4: P2 STRIVE Part B: Candidemia & Invasive Candidiasis trial design

    Week 1 2 3 4 5 6 7 8 9 Day 1 5 8 15 22 28 Dose Optional dose Mycological & clinical response Overall Response (Mycological & clinical response): 1° ENDPOINT Mycological & clinical response (IC only) 45 35 42 49 56 59 Mycological & clinical response Week 1 2 3 4 5 6 7 8 9 Day 1 5 8 15 22 28 45 35 42

  5. Slide 5: P2 STRIVE Part B: Candidemia & Invasive Candidiasis trial design

    Week 1 2 3 4 5 6 7 8 9 Day 1 5 8 15 22 28 Dose Optional dose Mycological & clinical response Overall Response (Mycological & clinical response): 1° ENDPOINT Mycological & clinical response (IC only) 45 35 42 49 56 59 Mycological & clinical response Week 1 2 3 4 5 6 7 8 9 Day 1 5 8 15 22 28 45 35 42

  6. Slide 6: STRIVE B: the bridge from STRIVE A to ReSTORE

    Rezafungin 400 / 200mg RESTORE (n=184) STRIVE B: the bridge from STRIVE A to ReSTORE Rezafungin 400 / 400mg Caspofungin 2017 2018 2019 2020 STRIVE B (n=91) STRIVE A (n=92) STUDY SIZE: STRIVE A + B (n=183) ≈ RESTORE (n=184) CRITERIA: Similar inclusion/exclusion, except STRIVE B enrolled patients with

  7. Slide 7: 30-Day All Cause Mortality (FDA endpoint)

    Similar to the ReSTORE trial primary endpoint for FDA 30-Day All Cause Mortality STRIVE B STRIVE A + B 7/43 1/15 5/33 12/76 2/46 8/61 n/N= n/N= Death at Day 30 (%) mITT Population 1 2 3 1 2 3 1. 400 mg dose once weekly for two to four weeks. 2. 400 mg dose for the initial week followed by 200 mg dos

  8. Slide 8: Investigator assessment of clinical response (EMA endpoint)

    Similar to the ReSTORE trial primary endpoint for EMA Investigator assessment of clinical response STRIVE B STRIVE A + B 28/43 13/15 23/33 53/76 37/46 43/61 n/N= n/N= Clinical Cure (%) at Day 14 mITT Population 1. 400 mg dose once weekly for two to four weeks. 2. 400 mg dose for the initial week fol

  9. Slide 9: STRIVE B primary endpoint: overall response

    STRIVE B primary endpoint: combination of clinical and mycological responses Overall response STRIVE B STRIVE A + B 27/43 13/15 23/33 46/76 35/46 41/61 n/N= n/N= Overall Success (%) at Day 14 mITT Population 1 2 3 1 2 3 1. 400 mg dose once weekly for two to four weeks. 2. 400 mg dose for the initial

  10. Slide 10: Topline summary of adverse events in safety population

    Topline summary of adverse events in safety population 400/400 mg (QWk) 400/200 mg (QWk) Pooled Groups N=46 N=18 N=64 n (%) All Related TEAEs 3 (6.5) 0 3 (4.7) Leading to study D/C 2 (4.3) 0 2 (3.1) Serious AE 1 (2.2) 0 1 (1.6) 70/50 mg (QD) N=34 n (%) 5 (14.7) 3 (8.8) 1 (2.9) REZAFUNGIN CASPOFUNGIN

  11. Slide 11: Phase 3 trial design mirrors the Phase 2 design

    Our Phase 3 trial design mirrors the Phase 2 design Phase 2 Week 1 2 3 4 5 6 7 8 9 1 Dose Optional dose Mycological & clinical response: 1° ENDPOINT All cause mortality Day 8 15 22 28 45 59 Phase 3 Week 1 2 3 4 5 6 7 8 9 Mycological & clinical response: 1° ENDPOINT EMA All cause mortality: 1° ENDPOI

  12. Slide 12: 30-Day All Cause Mortality – Post Hoc Analysis

    Rezafungin (STRIVE A + B, 400/200 only) vs. Caspofungin (STRIVE A + B) 30-Day All Cause Mortality – Post Hoc Analysis* SUPERIORITY NON-INFERIORITY 0 -20% 10% -10% -24.7% +0.41% FAVORS REZAFUNGIN FAVORS CASPOFUNGIN -8.8% 20% ReSTORE Phase 3 trial endpoint requires upper limit of confidence interval b

  13. Slide 13: Conclusions

    Conclusions Positive findings strongly support that once-weekly dosing of rezafungin is comparable to once-daily dosing of caspofungin Caspofungin cure rate at ~70% in both STRIVE A and B for Clinical Response is similar to its outcome in prior studies for candidemia/IC thereby validating the qualit

  14. Slide 14: Thank you

    New Hope for Serious Infections Topline Results: Phase 2 STRIVE Part B Trial for Rezafungin July 29, 2019 Thank you © Cidara Therapeutics 2019 | Confidential

Cidara Therapeutics — Technical Presentation (July 2019) on 6ix